Table 2.
Two-sample Mendelian randomization results for the effect of visceral adipose tissue on the risk of different types of cancer
| Outcomes | Methods | Odds ratio (95% CI) | P-value | q-valuea | Q-statistics | P h | Egger intercept | Pintercept |
|---|---|---|---|---|---|---|---|---|
| Ovarian cancer | MR-Egger | 1.13 (0.67–1.89) | 6.62E-01 | 1.66E-01 | 75.56 | 8.49E-02 | –0.001 (–0.015–0.015) | 9.90E-01 |
| Inverse-variance weighted | 1.12 (0.96–1.31) | 1.44E-01 | 1.13E-01 | 75.56 | 9.94E-02 | |||
| Weighted median | 1.05 (0.85–1.30) | 6.32E-01 | 5.25E-01 | |||||
| MR-PRESSO | 1.12 (0.97–1.30) | 1.38E-01 | 1.49E-01 | |||||
| Ovarian cancer | MR-Egger | 0.74 (0.14–3.84) | 7.23E-01 | 1.74E-01 | 68.79 | 2.31E-01 | 0.023 (–0.031–0.061) | 5.14E-01 |
| (Low-mucinous) | Inverse-variance weighted | 1.26 (0.78–2.03) | 3.52E-01 | 1.64E-01 | 69.27 | 2.46E-01 | ||
| Weighted median | 0.91 (0.44–1.89) | 7.94E-01 | 5.81E-01 | |||||
| Ovarian cancer | MR-Egger | 2.85 (0.67–12.10) | 1.61E-01 | 9.69E-02 | 65.77 | 3.15E-01 | –0.027 (–0.067–0.014) | 1.97E-01 |
| (Invasive mucinous) | Inverse-variance weighted | 1.14 (0.74–1.74) | 5.54E-01 | 1.85E-01 | 67.60 | 2.92E-01 | ||
| Weighted median | 1.65 (0.89–3.05) | 1.11E-01 | 1.92E-01 | |||||
| Ovarian cancer | MR-Egger | 1.91 (0.31–11.78) | 4.88E-01 | 1.45E-01 | 72.57 | 1.47E-01 | –0.025 (–0.076–0.026) | 3.44E-01 |
| (Low-serous) | Inverse-variance weighted | 0.82 (0.48–1.40) | 4.69E-01 | 1.78E-01 | 73.65 | 1.48E-01 | ||
| Weighted median | 0.93 (0.42–2.03) | 8.49E-01 | 5.98E-01 | |||||
| Ovarian cancer | MR-Egger | 0.84 (0.44–1.59) | 5.97E-01 | 1.59E-01 | 79.80 | 4.46E-02 | 0.007 (–0.011–0.025) | 4.48E-01 |
| (High-serous) | Inverse-variance weighted | 1.07 (0.88–1.29) | 5.03E-01 | 1.81E-01 | 80.57 | 4.74E-02 | ||
| Weighted median | 1.20 (0.92–1.55) | 1.74E-01 | 2.35E-01 | |||||
| MR-PRESSO | 1.08 (0.90–1.30) | 4.08E-01 | 2.71E-01 | |||||
| Ovarian cancer | MR-Egger | 1.80 (0.57–5.66) | 3.20E-01 | 1.16E-01 | 79.17 | 4.93E-02 | –0.002 (–0.034–0.031) | 9.13E-01 |
| (Endometrioid) | Inverse-variance weighted | 1.39 (1.00–1.94) | 4.97E-02 | 5.62E-02 | 79.19 | 5.87E-02 | ||
| Weighted median | 1.38 (0.86–2.21) | 1.78E-01 | 2.37E-01 | |||||
| Ovarian cancer | MR-Egger | 4.28 (0.94–19.58) | 6.55E-02 | 8.01E-02 | 71.17 | 1.75E-01 | –0.035 (–0.077–0.008) | 1.14E-01 |
| (Clear cell) | Inverse-variance weighted | 1.30 (0.83–2.04) | 2.49E-01 | 1.45E-01 | 74.17 | 1.38E-01 | ||
| Weighted median | 1.73 (0.91–3.29) | 9.73E-02 | 1.92E-01 | |||||
| Pancreatic cancer | MR-Egger | 6.19 (1.57–24.45) | 1.05E-02 | 3.79E-02* | 115.39 | 4.46E-01 | –0.030 (–0.05–0.001) | 4.72E-02 |
| Inverse-variance weighted | 1.65 (1.03–2.62) | 3.53E-02 | 4.80E-02* | 119.47 | 3.69E-01 | |||
| Weighted median | 2.23 (1.10–4.51) | 2.63E-02 | 1.92E-01 | |||||
| Breast cancer | MR-Egger | 0.66 (0.42–1.02) | 6.69E-02 | 8.05E-02 | 111.33 | 4.98E-06 | 0.013 (0.001–0.024) | 3.62E-02 |
| Inverse-variance weighted | 1.05 (0.94–1.17) | 4.00E-01 | 1.70E-01 | 121.02 | 4.76E-07 | |||
| Weighted median | 1.11 (0.98–1.26) | 9.09E-02 | 1.16E-01 | |||||
| MR-PRESSO | 1.06 (0.95–1.17) | 4.49E-01 | 1.92E-01 | |||||
| Breast cancer | MR-Egger | 0.67 (0.42–1.09) | 1.11E-01 | 9.10E-02 | 93.65 | 4.86E-04 | 0.012 (–0.001–0.025) | 6.46E-02 |
| (ER+) | Inverse-variance weighted | 1.05 (0.93–1.19) | 4.09E-01 | 1.71E-01 | 99.94 | 1.45E-04 | ||
| Weighted median | 1.02 (0.88–1.17) | 8.19E-01 | 5.89E-01 | |||||
| MR-PRESSO | 0.98 (0.88–1.10) | 7.61E-01 | 3.98E-01 | |||||
| Breast cancer | MR-Egger | 0.71 (0.41–1.24) | 2.38E-01 | 1.08E-01 | 62.39 | 2.30E-01 | 0.007 (–0.007–0.022) | 3.40E-01 |
| (ER–) | Inverse-variance weighted | 0.93 (0.81–1.07) | 3.00E-01 | 1.55E-01 | 63.43 | 2.31E-01 | ||
| Weighted median | 0.89 (0.72–1.09) | 2.54E-01 | 3.08E-01 | |||||
| MR-PRESSO | 0.90 (0.78–1.03) | 1.46E-01 | 1.53E-01 | |||||
| Lung cancer | MR-Egger | 1.21 (0.75–1.94) | 4.37E-01 | 1.37E-01 | 267.59 | 9.94E-04 | 0.006 (–0.009–0.106) | 9.12E-01 |
| Inverse-variance weighted | 1.24 (1.06–1.45) | 6.90E-03 | 1.56E-02* | 267.60 | 1.16E-03 | |||
| Weighted median | 1.21 (0.96–1.50) | 1.03E-01 | 1.92E-01 | |||||
| MR-PRESSO | 1.24 (1.07–1.45) | 4.81E-03 | 1.01E-02* | |||||
| Lung cancer | MR-Egger | 0.87 (0.44–1.76) | 7.07E-01 | 1.71E-01 | 253.86 | 8.85E-03 | 0.004 (–0.011–0.018) | 6.20E-01 |
| (Adenocarcinoma) | Inverse-variance weighted | 1.03 (0.82–1.30) | 7.79E-01 | 2.35E-01 | 254.17 | 9.71E-03 | ||
| Weighted median | 1.09 (0.78–1.51) | 6.11E-01 | 5.17E-01 | |||||
| MR-PRESSO | 1.09 (0.87–1.37) | 4.56E-01 | 2.84E-01 | |||||
| Lung cancer | MR-Egger | 1.62 (0.84–3.13) | 1.50E-01 | 9.59E-02 | 210.37 | 2.94E-01 | –0.002 (–0.016–0.012) | 7.59E-01 |
| (Squamous-cell carcinoma) | Inverse-variance weighted | 1.47 (1.20–1.82) | 3.22E-04 | 1.46E-03* | 210.47 | 3.09E-01 | ||
| Weighted median | 1.32(0.94–1.86) | 1.13E-01 | 1.92E-01 | |||||
| MR-PRESSO | 1.44 (1.17–1.76) | 6.50E-04 | 2.72E-03* | |||||
| Colorectal cancer | MR-Egger | 1.32 (0.76–2.30) | 3.21E-01 | 1.16E-01 | 223.75 | 2.45E-01 | –0.005 (–0.017–0.007) | 3.90E-01 |
| Inverse-variance weighted | 1.05 (0.88–1.26) | 5.78E-01 | 1.87E-01 | 224.54 | 2.49E-01 | |||
| Weighted median | 0.99 (0.74–1.33) | 9.47E-01 | 6.24E-01 | |||||
| Prostate cancer | MR-Egger | 0.85 (0.64–1.13) | 2.69E-01 | 1.12E-01 | 128.39 | 1.66E-03 | 0.004 (–0.004–0.122) | 2.89E-01 |
| Inverse-variance weighted | 0.99 (0.91–1.07) | 7.51E-01 | 2.28E-01 | 130.11 | 1.51E-03 | |||
| Weighted median | 0.99 (0.88–1.11) | 8.19E-01 | 4.85E-01 | |||||
| MR-PRESSO | 0.98 (0.90–1.07) | 6.61E-01 | 5.89E-01 |
a
Estimated by the false discovery rate (FDR) method for multiple testing correction.
*
q-value < 0.05.
ER, oestrogen receptor; NA, not applicable; Ph, P-value for heterogeneity; Pintercept, P-value for intercept of MR-Egger regression.